Study identification

PURI

https://redirect.ema.europa.eu/resource/26292

EU PAS number

EUPAS4869

Study ID

26292

Official title and acronym

Using real-life patient records to help identify predictors of future exacerbation risk (Asthma risk predictors)

DARWIN EU® study

No

Study countries

United Kingdom

Study description

Background: Increased understanding of exacerbation patterns and the individual and clusters of risk factors associated with them could help to define ‘frequent exacerbators’ more meaningfully (e.g. as a persistent group of patients at the high end of the control continuum, or a dynamic group population made up of patients experiencing disease phases during which their exacerbation risk is elevated due to specific triggers). Improved understanding of the relationships between patient characteristics and frequent exacerbation risk will help to inform the development of new assessment tools, treatment strategies and interventions aimed at reducing the significant morbidity (and cost) associated with asthma exacerbations.This study aims to identify patient characteristics recorded within routine primarycare datasets that are associated with increased risk of frequent asthmaexacerbations, with the ultimate goal of:1. Characterising the frequent exacerbator subgroup of asthma patients2. Identifying individual risk factors associated with increased futureexacerbation risk3. Exploring clusters of risk factors associated with increased risk of futureexacerbation risk.

Study status

Finalised
Research institution and networks

Institutions

Networks

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published:
04/06/2024
Network
ENCePP partner

Contact details

Kathryn Richardson

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Other

More details on funding

Respiratory Effectiveness Group (REG), Research in Real Life Ltd
Study protocol
Initial protocol
English (1.8 MB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable